Who’s Going to BIO‑Europe 2026

Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website

392 companies and 386 speakers at BIO-Europe 2026, a ~5,800-person partnering meeting of European biotech and pharma dealmakers and investors. As of Sep 29, 2026.

Showing 1–10 of 392 organizations

Organization	BIO-Europe 2026 Attendance
Merck KGaA Darmstadt, Germany	◆Platinum Sponsor
merckgroup.com/en/company/partnering/collaboration/collaboration-in-healthcare/strategic-focus-and-partnerships.html Large pharmaPlatinum sponsor Science and technology company active in healthcare, life science and electronics; operates as EMD Serono and MilliporeSigma in North America.	Talk Mon Nov 9 15:00–16:15 Merck's EMEA Advance Biotech Grant Program Five young biotech companies pitch their science to Merck, competing for a grant that helps them bring a product to market. with Stemmatters, ConvEyXO, Procavea Biotech +3 more Panel Mon Nov 9 13:00–13:45 Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery. with MichBio, XGEN Venture, Boehringer Ingelheim Panel Tue Nov 10 14:00–14:45 Immunology under the microscope: New frontiers What is new in drugs for autoimmune and inflammatory diseases: emerging targets, recent trial results, and where companies are investing and partnering. with MRM Health, Hansa Biopharma, Claris Ventures Panel Tue Nov 10 16:00–16:45 Unlocking Clinical Trial Systems How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely. with AstraZeneca Panel Wed Nov 11 09:00–09:45 From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance. with FRESCI, European Commission, European Medicines Agency
Bayer Leverkusen, Germany	◆Platinum Sponsor
bayer.com Large pharmaPlatinum sponsor Life sciences company with pharmaceuticals, consumer health and crop science divisions.	Talk Tue Nov 10 09:00–09:30 An Outlook into the Year 2050: Navigating the Future of Efficiency and Innovation How AI, global expansion and patient community outreach may reshape the way clinical trials are run, and what to change now to prepare. Panel Tue Nov 10 15:00–15:25 Inside the Incubator: What It Really Takes to Build a Biotech Company Today What incubators backed by big drug companies look for in young biotechs, and how they help founders with money, advice and partners. with Phinomics Panel Tue Nov 10 17:00–17:45 Resilient by Design: Reinventing Biopharma Alliances in a Fragmenting World How drug companies are reshaping research and manufacturing partnerships to stay reliable as political tensions and supply chain risks divide the world. with Handelsblatt, Angelini Ventures, Evotec +1 more Business of BiotechBiomanufacturing Strategy Panel Tue Nov 10 16:30–16:55 The Role of Innovation in Biopharma Growth How new ideas and technologies drive growth for drug companies, and how to keep innovating while scaling up, with real examples. Panel Wed Nov 11 10:00–10:45 AI Regulations: Driving Innovation While Navigating Compliance What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation. with European Medicines Agency Panel Wed Nov 11 09:00–10:00 Collaborative Innovation in CDMO Partnerships How drug companies and contract manufacturers develop new therapies together, with examples of what makes these partnerships work and where they struggle. with Eleva, Evotec
European Medicines Agency Amsterdam, Netherlands
ema.europa.eu Gov, delegations & associations EU agency that evaluates and supervises medicines for human and veterinary use.	Panel Mon Nov 9 11:00–11:45 Unlocking Pharma’s Productivity Potential Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive. with Norstella, M Ventures, Novo Nordisk +1 more Business of Biotech Panel Tue Nov 10 13:00–13:45 Aligning with Regulators to Propel Innovation What help and incentives the European Medicines Agency offers developers of new treatments, and how to use them on the road to approval. with MSD Panel Tue Nov 10 14:00–14:45 Harnessing Regulatory Sandboxes to Drive Innovation in Novel Therapeutics & Technologies How regulatory sandboxes, where regulators let new products be tested under adjusted rules, could support new therapies and health technologies in Europe. with HTW Berlin, Innovative Health Initiative, CSL Behring Panel Wed Nov 11 10:00–10:45 AI Regulations: Driving Innovation While Navigating Compliance What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation. with Bayer Panel Wed Nov 11 09:00–09:45 From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance. with FRESCI, Merck KGaA, European Commission
Boehringer Ingelheim Ingelheim am Rhein, Germany	◆Platinum Sponsor
boehringer-ingelheim.com/partnering/human-health-partnering Large pharmaPlatinum sponsor Family-owned pharmaceutical company developing human and animal health medicines.	Panel Mon Nov 9 13:00–13:45 Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery. with MichBio, XGEN Venture, Merck KGaA Talk Tue Nov 10 13:00–14:00 Biologics Manufacturing Excellence How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently. with Immatics, Pfizer, Rezon Bio Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. with Micro CRISPR, AAVantgarde Bio, Inveready +1 more Panel Wed Nov 11 10:00–10:45 Most Favoured Nations: A Game-Changer for Biotech Dealmaker? How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans. with EUCOPE, Astellas, Bristol Myers Squibb
Johnson & Johnson New Brunswick, NJ	◇Silver Sponsor
jnj.com Large pharmaSilver sponsor Healthcare company developing innovative medicines and medical technologies; its Innovation unit partners with external researchers and start-ups.	Panel Mon Nov 9 16:15–17:00 Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work? What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies. with 59 North Communications, Gateway Factory, Grove Biopharma +2 more Panel Tue Nov 10 10:00–10:25 Regulatory Updates for Orphan and Paediatric Medicines How updated EU drug laws change the rewards for rare-disease and children's medicines, such as longer protection from competing copies. Panel Wed Nov 11 10:00–10:45 Envisioning the future of ophthalmology What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise. with Micro CRISPR, Boehringer Ingelheim, AAVantgarde Bio +1 more Panel Wed Nov 11 13:00–13:45 What's Next for Biomanufacturing Strategies? Where the manufacturing of biological medicines is heading, from sturdier supply chains and industry mergers to AI and new ways to scale up. with Resolution Therapeutics, Sandoz, Valneva
Novo Nordisk Bagsværd, Denmark	◆Gold Sponsor
novonordisk.com Large pharmaGold sponsor Danish pharmaceutical company, branded Novo since September 2026, making medicines for diabetes, obesity and rare diseases.	Panel Mon Nov 9 11:00–11:45 Unlocking Pharma’s Productivity Potential Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive. with Norstella, M Ventures, Blackstone Life Sciences +1 more Business of Biotech Panel Tue Nov 10 15:30–15:55 Accelerating Innovation: Creating the Right Environment for Success in Biopharma Partnerships How to design partnerships that work, from payments tied to research milestones and shared risk to guarding intellectual property while sharing ideas. Panel Tue Nov 10 10:00–10:45 Cardiometabolic innovations beyond GLP-1 – Where are we now? Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going. with LifeArc, Atrogi, IsomAb +2 more Panel Tue Nov 10 15:00–15:45 Longevity – Are we getting younger? What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape. with Longevity.Technology, Asabys Partners, Chrysea +1 more
AstraZeneca Cambridge, United Kingdom
astrazeneca.com Large pharma Global pharmaceutical company developing medicines in oncology, cardiovascular, renal, respiratory, immunology and rare diseases.	Panel Mon Nov 9 17:00–17:45 AI in the Lab: Why Greater Efficiency Could Mean More Drugs, Not Fewer Scientists Why AI that forms hypotheses and guides experiments could mean more drug candidates, not fewer scientists, and how to pick which to pursue. with Evaluate, Ingenix, Sofinnova Partners Ecosystem InnovationBusiness of Biotech Panel Tue Nov 10 16:00–16:45 Unlocking Clinical Trial Systems How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely. with Merck KGaA Panel Wed Nov 11 11:00–11:30 Sustainability & Innovation: Transforming Biopharma Partnerships for a Greener Future How drug companies, smaller firms and suppliers can team up to cut supply chain carbon emissions and bring greener technologies to industrial scale.
EUCOPE Brussels, Belgium
eucope.org Gov, delegations & associations Trade association representing small and mid-sized innovative pharmaceutical and biotech companies in Europe.	Panel Tue Nov 10 10:30–10:55 Addressing Unmet Medical Needs in Europe’s Evolving Pharmaceutical Landscape How regulators judge which diseases lack good treatments, which faster approval routes apply, and whether recent EU drug law changes have helped. with PTC Therapeutics Panel Wed Nov 11 13:00–13:45 HTA Regulation: Early Insights and Reimbursement Implications Early lessons from the EU's new joint reviews of how much new drugs help patients, and whether they ease or hinder patient access. with Lundbeck Panel Wed Nov 11 10:00–10:45 Most Favoured Nations: A Game-Changer for Biotech Dealmaker? How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans. with Astellas, Bristol Myers Squibb, Boehringer Ingelheim
Miltenyi Biomedicine Bergisch Gladbach, Germany
miltenyibiomedicine.com Biotech Clinical-stage company of the Miltenyi Group developing CAR-T and other cell therapies for cancer and autoimmune disease.	Panel Tue Nov 10 10:00–10:45 Accelerating Access to Innovative Therapies for European Patients Through Integrated Decision-Making How approval, benefit reviews and pricing decisions could run side by side instead of one after another, so European patients get new medicines sooner. with IGES Institut, Krystal Biotech, EFPIA +1 more Panel Tue Nov 10 09:30–09:55 From Clinical Success to Commercial Readiness: Strategic Lessons in Bringing Advanced Therapies to Patients Lessons from preparing cell and gene therapies for launch by planning manufacturing, approval and reimbursement alongside the clinical trials. Talk Wed Nov 11 09:30–09:55 Bridging Therapeutic Areas: Navigating the Oncology–Autoimmune Convergence in Cellular Therapies What changes when cell therapies first developed for cancer move into autoimmune disease, from acceptable safety risks and trial endpoints to manufacturing.
Sofinnova Partners Paris, France
sofinnovapartners.com Investors & finance Life sciences venture capital firm investing from seed to late stage in biotech, medtech and industrial biotech.	Panel Mon Nov 9 17:00–17:45 AI in the Lab: Why Greater Efficiency Could Mean More Drugs, Not Fewer Scientists Why AI that forms hypotheses and guides experiments could mean more drug candidates, not fewer scientists, and how to pick which to pursue. with Evaluate, AstraZeneca, Ingenix Ecosystem InnovationBusiness of Biotech Panel Mon Nov 9 16:00–16:45 Cell and Gene Therapy: What Should You Know? Where cell and gene therapies stand today, what recent clinical and sales data show, and how funding and partnerships are changing. with Form Bio, BioM, VeonGen Therapeutics Panel Mon Nov 9 16:00–16:45 Fuelling Innovation: The State of Early-Stage Investment in Biotech Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting. with European Innovation Council, Eir Ventures, Earlybird Venture Capital +2 more

Instantly find 20 buyers from companies at BIO-Europe 2026

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

What conference is this?

BIO-Europe is EBD Group’s annual European biotech partnering conference, held November 9–11, 2026 at Koelnmesse in Cologne. Most of its value is in pre-arranged one-to-one partnering meetings between biotech and pharma business-development teams and investors; the program adds panels and talks on the business of biotech, ecosystem innovation, therapeutics, biomanufacturing, clinical and regulatory strategy.

What is in this guide?

Every organization we can place at BIO-Europe 2026: 386 speakers from the public speaker list and agenda (101 sessions) rolled up to their companies and institutions, plus the 119 sponsors, delegations and supporters from the public sponsor list with their tier — 392 organizations in one list. Speakers appear as job titles, never by name. The partnering attendee list needs a login and is not included. Speakers from the company presentations are listed with their organizations; their time slots are added when EBD publishes them.

How are organizations typed?

By the role an organization plays at a partnering meeting: drug developers (large pharma and biotech), investors, the service providers around them — CDMOs and CROs, tools, data and AI companies, consulting, legal and other services — and academic, government and association bodies, including national and regional delegations. The track filters come from the track an organization speaks in.

How current is it?

Pulled from the public agenda, speaker list and sponsor list on September 29, 2026.

Browse BIO-Europe 2026 by

Organization type

Track

Everyone

All organizations A–Z 392

Organizations with their own page

150 organizations — every exhibitor and every organization with 2 or more presentations.

Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction